These unexpected findings spurred Merck to initiate a Phase III randomized, double-blind, multicenter trial to further evaluate the efficacy of MK-1084 in combination with Pembrolizumab versus Pembrolizumab plus placebo in previously untreated NSCLC patients with a KRAS G12C mutation and a PD-L1 TPS of ≥50%. Here, KRAS is linked to non-small cell lung carcinoma.